DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Contract Development And Manufacturing Organization (CMO) Global Market Report 2020-30: Covid 19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the global pharmaceutical contract development and manufacturing market as it emerges from the Covid-19 shut down.
The global pharmaceutical contract development and manufacturing market is expected to decline from $99.8 billion in 2019 to $93 billion in 2020 at a compound annual growth rate (CAGR) of -7%. The decline is mainly due to the focus on Covid-19 outbreak and its treatment across the globe, and disruption in the supply chain owing to geographical trade barriers affecting the supply of APIs and raw materials for drug manufacturing. Sponsors contracting CMOs are pausing the drug development activities due to Covid19 or restructuring the current drug development plans. The market is then expected to recover and reach $128.4 billion in 2023 at a CAGR of 6.5%.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3 working days of order.
The companies in the pharmaceutical contract development and manufacturing market are investing towards acquiring and forming alliances with other companies in the market. The pharmaceutical contract development and manufacturing companies are following the trend of merger and acquisition in order to expand their global market reach to meet the client needs, to increase their production capabilities while maintaining cost efficiencies and to get access to latest technology and new services. The high level of merger and acquisition activities are resulting in consolidation of the contract service providers.
The pharmaceutical contract development and manufacturing market is restricted by the poor-capacity utilization of manufacturing facilities. The capacity utilization is calculated considering the full potential capacity of the production plant. The poor-capacity utilization of the production plant is caused due to the inefficiency of different sub-processes in the production line which results in low production. The low production output results in low revenue generation for the production unit, affecting the overall pharmaceutical contract development and manufacturing market. For instance, according to an article by the Trade Promotion Council of India (TPCI) most of the pharmaceutical production units in India run at 30-40% of their capacity. Therefore, the under usage of capacity of production plant negatively affects the pharmaceutical contract development and manufacturing market.
The growth of the pharmaceutical contract development and manufacturing market is driven by the increase in the demand for medicines across the globe. The high prevalence of diseases and the need for a longer lifespan increased the demand for medicines pushing the pharmaceutical companies to increase the production of existing drugs and rise the investment in their R&D to promote the development of new drugs. This impels the pharmaceutical companies to collaborate with contract manufacturing organizations (CMOs) as a way to lower operational costs, thus, increasing the demand in pharmaceutical contract development and manufacturing market.
Key Topics Covered:
1. Executive Summary
2. Pharmaceutical Contract Development And Manufacturing Market Characteristics
3. Pharmaceutical Contract Development And Manufacturing Market Size And Growth
3.1. Global Pharmaceutical Contract Development And Manufacturing Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Pharmaceutical Contract Development And Manufacturing Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market
4. Pharmaceutical Contract Development And Manufacturing Market Segmentation
4.1. Global Pharmaceutical Contract Development And Manufacturing Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5. Pharmaceutical Contract Development And Manufacturing Market Regional And Country Analysis
5.1. Global Pharmaceutical Contract Development And Manufacturing Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Pharmaceutical Contract Development And Manufacturing Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
Companies Mentioned
- Recipharm AB
- Pfizer Inc.
- Boehringer Ingelheim International GmbH.
- Aenova Group
- Famar
- Jubilant Life Sciences Limited,
- Catalent Pharma Solutions
- Chemicals Limited
- Dishman Pharmaceuticals
- HAUPT Pharma AG
- Kemwell Pvt. Ltd.
- Nipro Corp.
- NextPharma
- Royal DSM N.V
- Althea Technologies
- Thermo Fisher Scientific Inc.
- Lonza Group Ltd
- AbbVie Inc.
- Consort Medical plc
- Almac Group
- Siegfried Holding AG
- Evonik Industries AG
- Vetter Pharma International GMBH
For more information about this report visit https://www.researchandmarkets.com/r/7hrcx4
